State
72,919 recalls have nationwide distribution and so reach Idaho. 3,517 additional recalls listed Idaho specifically in their distribution scope.
Of the 3,517 recalls naming Idaho we have scored against our rubric, 364 (10%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 1,023 (29%) are Severe.
Which agencies issued them
These figures cover only the 3,517 recalls whose distribution notice names Idaho specifically. The 72,919 nationwide recalls listed below reach every state, so counting them here would make every state page show the same numbers.
Audi is recalling certain 2019-2024 e-tron and Q8 e-tron vehicles because an improperly assembled fastener can cause the brake pedal to detach from the brake booster.
Fresenius Kabi USA, LLC is recalling certain batches of 0.9% Sodium Chloride Injection due to concerns regarding sterility assurance.
Fresenius Kabi is recalling 0.45% Sodium Chloride Injection, USP in 250 mL freeflex bags, citing lack of assurance of sterility.
Stryker Sustainability Solutions is recalling Color Cuff tourniquet cuffs because the cuff can detach from the bladder at the welding connection, leaving it unable to maintain pressure.
Winnebago is recalling 2027 Suncruiser and 2026-2027 Sunflyer motorhomes because side reflectors may be missing, reducing visibility to other drivers.
Fresenius Kabi is recalling 0.9% Sodium Chloride Injection, USP in 50 mL presentation, citing lack of assurance of sterility. Two batches are affected.
Preferred Pharmaceuticals is recalling six lots of Artificial Tears Lubricant Eye Drops manufactured by Geri-Care, citing lack of assurance of sterility. 720 bottles are affected.
B.R.A.H.M.S PlGF Plus KRYPTOR in vitro diagnostic tests are being recalled after customers observed out-of-range values at the lowest quality control level, which can contribute to falsely elevated results.
Fresenius Kabi is recalling 0.9% Sodium Chloride Injection, USP in 1,000 mL single dose freeflex bags distributed by Fresenius Medical Care RTG, citing lack of assurance of sterility.
A circuit board issue in Multi-parameter Command Module model 91496 can start cardiac output measurement early in Auto mode, producing errors and inaccurate readings. 1,790 units are affected.
Fresenius Kabi is recalling 0.9% Sodium Chloride Injection, USP in 100 mL single dose freeflex bags distributed by BD, citing lack of assurance of sterility.
Fresenius Kabi is recalling one batch of 0.9% Sodium Chloride Injection, USP in 1,000 mL single dose freeflex bags distributed by BD, citing lack of assurance of sterility.
Tornier HRS Max tuberosity bodies and a trial component were incorrectly labeled as HRS Max products; they are compatible only with the Tornier HRS system. 233 units are affected.
Fagron is recalling Vancomycin HCl 1.25 grams in 250 mL sodium chloride bags for lack of assurance of sterility and because a blue break-off part could detach from the administration port.
Fresenius Kabi is recalling 0.9% Sodium Chloride Injection, USP, 250 mL single dose freeflex bags distributed by BD, citing lack of assurance of sterility.
Viatris is recalling one lot of Xanax XR (alprazolam) extended-release tablets, 3 mg, after the product failed dissolution specifications.
Cipla is recalling Lanreotide Injection 120 mg/0.5 mL prefilled syringes supplied with a safety needle, citing lack of assurance of sterility. 54,583 syringes are affected.
Fagron is recalling norepinephrine bitartrate 16 mg in 250 mL sodium chloride bags for lack of assurance of sterility and because a blue break-off part could detach from the administration port.
Fresenius Kabi is recalling 5% Dextrose Injection, USP, 2.5 g per 50 mL supplied in 100 mL freeflex bags, citing lack of assurance of sterility.
Fresenius Kabi is recalling 0.9% Sodium Chloride Injection, USP supplied in 500 mL freeflex bags under its own label, citing lack of assurance of sterility.
GE Healthcare is recalling Omnipaque (iohexol) Injection, 300 mg/mL, over the presence of particulate matter. The action covers 866,570 vials distributed nationwide.
Fresenius Kabi is recalling 0.9% Sodium Chloride Injection, USP supplied in 250 mL freeflex bags under its own label, citing lack of assurance of sterility.
Cipla is recalling Lanreotide Injection 120 mg/0.5 mL prefilled syringes for lack of assurance of sterility, following an FDA observation of deficiencies in visual inspection at the contract manufacturing site.
Fagron is recalling norepinephrine bitartrate 32 mg in 250 mL sodium chloride bags for lack of assurance of sterility and because a blue break-off part could detach from the administration port.
Fresenius Kabi is recalling 0.9% Sodium Chloride Injection, USP supplied in 100 mL freeflex bags under its own label, citing lack of assurance of sterility.